Cantargia (STO: CANTA) has announced that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and at risk of developing lung cancer.
The study is an investigator-led initiative in collaboration with Drs. Robert Samstein, Thomas Marron and Miriam Merad at Mount Sinai Tisch Cancer Center, New York.
In a statement, Hilde Steineger, CEO of Cantargia, commented, “Building on the encouraging clinical findings in patients with solid tumors, together with robust preclinical data, we are eager to evaluate nadunolimab as a preventive treatment in this high risk population. We are excited that a leading institution such as the Tisch Cancer Institute recognizes nadunolimab as an innovative and promising therapeutic approach, and we look forward to advancing this treatment option further.”
Dr. Robert Samstein, Mount Sinai Tisch Cancer Center, remarked, “Lung cancer is a leading killer and while treatment options have improved, most lives are saved by early detection. The scientific rationale for using a novel IL1RAP-targeting approach with nadunolimab is compelling in this identified high-risk population, and we look forward to starting the study.”
